线粒体蛋白酶ClpP是治疗多发性骨髓瘤的有希望的目标
Xiang Liu1, Jinlong Gu2, Song Liu2
1Department of Hematology/Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Biochemical pharmacology
|March 7, 2025
概括
一种新型化合物,7b,向线粒体病原分解蛋白酶P (ClpP),有效地杀死多发性骨髓瘤 (MM) 细胞,包括耐药类型. 这种ClpP激活为复发性和耐火性MM提供了一个有前途的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
- 线粒体生物学 线粒体生物学
背景情况:
- 耐药性和复发是多发性骨髓瘤 (MM) 治疗的重大挑战,需要新的治疗方法.
- 线粒体氨酸解质蛋白酶P (ClpP) 激活在各种瘤中显示出抗癌潜力,但其在MM中的作用尚未得到充分研究.
研究的目的:
- 调查ClpP在MM中的作用,并评估新型ClpP激动剂作为潜在的抗MM剂.
- 确定和描述一种强大的ClpP激活剂,用于治疗耐药性和复发性多发性骨髓瘤.
主要方法:
- 合成和选ClpP激活剂以确定强大的抗MM化合物.
- 在体外评估化合物7b对MM细胞的影响,包括ClpP激活,线粒体功能和细胞死亡途径.
- 在耐药性MM细胞系和体内小鼠模型中评估7b化合物的疗效.
主要成果:
- 在MM患者中,ClpP表达升高,特别是在复发病例中.
- 化合物7b强烈激活了ClpP,导致线粒体蛋白质降解,氧化酸化 (OXPHOS) 损害,线粒体膜潜力 (MMP) 崩和活性氧物种 (ROS) 的增加.
- 7b诱导了以线粒细胞衰变为媒介的MM细胞死亡,并证明了对抗抗托雷佐米布和莱纳利多米德耐药的MM细胞的有效性,在体内耐受性良好.
结论:
- 针对ClpP是一种有前途的治疗策略,用于多发性骨髓瘤.
- 化合物7b是一种强大的ClpP激活剂,具有显著的抗MM活性,特别有效于对复发性和耐药性疾病.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitochondrial Precursor Proteins
2.5K
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70 chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial...
Most of the mitochondrial...
2.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Translocation of Proteins into the Mitochondria
3.0K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.0K
Electron Transport Chain: Complex I and II
10.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.0K


